Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Hematology Innovation: Pipeline overview Ophthalmology ganaplacide - Imidazolopiperazines derivative Study Indication Phase Patients Primary Outcome Measures NCT03167242 (CKAF156A2202) Malaria Phase 2 PCR-corrected adequate clinical and parasitological response (ACPR) NCT04546633 KALUMI (CKAF156A2203) Malaria, uncomplicated Phase 2 References Abbreviations Biosimilars Global Health PCR-corrected and uncorrected Adequate Clinical and Parasitological Response (ACPR) KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition Malaria patients 12 to < 18 years old with malaria caused by P. falciparum Arms Intervention KAF156 and LUM-SDF (different combinations) Coartem Target Patients Adults and children with uncomplicated Plasmodium falciparum malaria Read-out Milestone(s) H2-2021 (actual) 2023 Publication CSR final in CREDI 20Dec2021 TBD 119 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation